Aardvark Therapeutics’ (AARD) “Neutral” Rating Reaffirmed at HC Wainwright

Aardvark Therapeutics (NASDAQ:AARD)‘s stock had its “neutral” rating reissued by stock analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They presently have a $6.00 price objective on the stock. HC Wainwright’s target price would indicate a potential upside of 2.39% from the stock’s previous close.

A number of other equities research analysts have also issued reports on the stock. BTIG Research lowered shares of Aardvark Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 15th. Weiss Ratings raised Aardvark Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 2nd. B. Riley Financial reduced their price objective on Aardvark Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. Finally, Morgan Stanley reiterated an “underweight” rating and issued a $3.00 target price (down from $7.00) on shares of Aardvark Therapeutics in a report on Friday, May 15th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $16.30.

Aardvark Therapeutics Price Performance

Shares of Aardvark Therapeutics stock opened at $5.86 on Monday. The stock has a market capitalization of $128.22 million, a price-to-earnings ratio of -1.83 and a beta of 3.93. The business has a 50-day moving average of $4.82 and a 200 day moving average of $7.52. Aardvark Therapeutics has a 12 month low of $3.35 and a 12 month high of $17.94.

Aardvark Therapeutics (NASDAQ:AARD) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.99) earnings per share (EPS) for the quarter. Equities research analysts anticipate that Aardvark Therapeutics will post -3.46 earnings per share for the current year.

Hedge Funds Weigh In On Aardvark Therapeutics

Large investors have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Aardvark Therapeutics during the second quarter worth about $42,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Aardvark Therapeutics in the 4th quarter valued at about $47,000. Persistent Asset Partners Ltd purchased a new position in Aardvark Therapeutics during the 4th quarter worth approximately $56,000. New York State Common Retirement Fund acquired a new position in Aardvark Therapeutics during the second quarter worth approximately $99,000. Finally, MetLife Investment Management LLC acquired a new stake in shares of Aardvark Therapeutics in the fourth quarter valued at approximately $102,000.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.